PTPN11 and neoplasm: Expression of the SHP2 mutant in cancer cells dramatically attenuated immune-mediated tumor killing upon SHP099 treatment (Fig. 1h), suggesting that inhibition of SHP2 in the cancer cell is critical for SHP099 to enhance tumor cell killing by T cells.